Bio-gene Technology Ltd. · ASX:BGT
Bio-gene Technology — Investor Presentation (October 2018)
20 slides from Bio-gene Technology's investor presentation, Oct 15, 2018
Slide 1: ASX Announcement: Updated Company Presentation October 2018
ASX ANNOUNCEMENT 15 OCTOBER 2018 UPDATED COMPANY PRESENTATION – OCTOBER 2018 For personal use only Bio-Gene Technology Limited (ASX: BGT, “Bio-Gene”) is releasing the attached Updated Company Presentation in anticipation of a series of investor briefings which will take place over the next couple of
Slide 2: Investor Presentation October 2018
For personal use only (ASX:BGT) Investor Presentation October 2018
Slide 3: The Global Problem of Pest Control
The Global Problem of Pest Control For personal use only The Ag-Chem industry is seeking new & safer Pest Environmental chemistry as global resistance Resistance Impact continues to worsen Pests are rapidly Public outrage at incumbent developing resistance to products’ toxic impact on bees current i
Slide 4: In recent years the problem has worsened
In recent years the problem has worsened For personal use only Increasing number of resistant species New insecticides are increasingly elusive 700 160,000 Species Resistant Molecules Screened 586 insect species now >140,000 molecules must resistant to at least one 140,000 600 be screened to discove
Slide 5: New compounds must demonstrate multiple qualities
New compounds must demonstrate multiple qualities For personal use only Safe Novel Mode Efficacy Scalability Chemistry of Action Compound must New ‘soft chemistries‘ Compounds must Technology must be effective, are required, have a novel Mode be able to be either alone or which don’t of Action (MoA)
Slide 6: Bio-Gene's technology addresses these needs
Bio-Gene’s technology addresses these needs For personal use only Safe Novel Mode Efficacy Scalability Chemistry of Action Data shows Flavocide™ Trials show relatively Bio-Gene’s compounds CSIRO collaboration & Qcide™ are highly low toxicity to operate via a has refined effective for controlling bee
Slide 7: Bio-Gene has two unique compounds
Bio-Gene has two unique compounds For personal use only Qcide™ Flavocide™ Natural Compound Nature Identical Compound Extract of an A chemical process is Australian eucalypt: used to produce a ‘Gypmie Messmate’ ‘synthetic copy’ of the compound that can be Qcide™ is well suited mass produced to applic
Slide 8: Well-defined pathway to commercialisation
Well-defined pathway to commercialisation For personal use only Testing & Data Generation Well Create suite of trial data & IP relating to efficacy, toxicity, mode of action and manufacturing Progressed Introductory Commercial Discussions Globally Present Bio-Gene to major Ag-Chem, Government Agenci
Slide 9: Bio-Gene has delivered on multiple milestones in 2018
Bio-Gene has delivered on multiple milestones in 2018 For personal use only Significant Suite of Trial Data Toxicology Studies to Multiple Partnership for Proof of Concept Support Registration Discussions Efficacy Testing Expanded Knowledge Strengthened Improved Appointed Expert of Mode of Action In
Slide 10: Trial Data for Proof of Concept Efficacy Testing
Trial Data for Proof of Concept Efficacy Testing For personal use only Objective Demonstrate effectiveness against pests that are resistant to other classes of chemistry Create suite of testing data across key verticals, to de-risk technology, & support discussions with major Ag-Chem businesses Resu
Slide 11: Toxicology Studies to Support Registration
Toxicology Studies to Support Registration For personal use only Objective Demonstrate the safety of the technology & fulfil registration requirements Achieved in 2018 Continued formal toxicology & environmental safety studies with accredited third parties to perform necessary testing: • 28-day Or
Slide 12: Multiple Partnership Discussions
Multiple Partnership Discussions For personal use only Objective Identify appropriate partners for product evaluation & development Achieved in 2018 Held multiple meetings in Australia, Europe, US & Asia, with Major Ag-Chem Producers, Government agencies & Not-for-Profit Organisations, covering al
Slide 13: Expanded Knowledge of Mode of Action
Expanded Knowledge of Mode of Action For personal use only Objective Clarify the specifics of the Mode of Action (“MoA”) to apply for a new class of chemistry via IRAC & support IP portfolio Achieved in 2018 • MoA confirmed via electrophysiological testing by world-class group • Supported by multi
Slide 14: Strengthened Intellectual Property
Strengthened Intellectual Property For personal use only Objective Generate data to support current & future patent filings & Intellectual Property Achieved in 2018 Two additional patent applications lodged Significant manufacturing Intellectual Property Next Steps Continue to identify opportuniti
Slide 15: Improved Manufacturing Capability
Improved Manufacturing Capability For personal use only Objective Improve cost & yield of current manufacturing processes for Qcide™ & Flavocide™ Achieved in 2018 • Partnership with CSIRO has delivered substantial improvement in the cost of production of Flavocide™ with improved purity and yield •
Slide 16: Appointed Expert Advisors
Appointed Expert Advisors For personal use only Objective Engage specialists in related fields to assess data & assist with next stage testing DOUG RATHBONE PROF. CATHERINE HILL NEIL ANDERSON Advisor to the BGT Board Purdue University Chemistry & BGT Scientific Advisory Manufacturing Consultant Boar
Slide 17: Q&A
Q&A For personal use only *Click links to launch Articles 16
Slide 18: Financial Overview
Financial Overview For personal use only Strong Cash Position $0.30 2 Volume (m) BGT has a well funded balance sheet with ~$6.7m in cash (as at end FY18), $0.20 providing a ~2 year runway 1 $0.10 Capital Structure & Financials Shares on Issue 128m $- 0 Nov-17 Feb-18 May-18 Aug-18 Share Price (Oct-18
Slide 19: Board & Management
Board & Management For personal use only DON BRUMLEY RICHARD JAGGER PETER MAY Non-Executive Chairman CEO & Managing Director Executive Director, R & D • 25+ years as a senior partner & leader of • 20+ years working in agriculture globally • 20+ years experience in crop protection Ernst & Young – Oce
Slide 20: For personal use only
For personal use only Richard Jagger Roger McPherson CEO CFO, Co. Sec. +61 3 9628 4178 +61 3 9628 4178 richardj@bio-gene.com.au rogerm@bio-gene.com.au
Bio-Gene Technology — Investor Presentation (October 2018) on 6ix